全文获取类型
收费全文 | 3516445篇 |
免费 | 297370篇 |
国内免费 | 14489篇 |
专业分类
耳鼻咽喉 | 49550篇 |
儿科学 | 109135篇 |
妇产科学 | 93174篇 |
基础医学 | 549277篇 |
口腔科学 | 99962篇 |
临床医学 | 312510篇 |
内科学 | 620389篇 |
皮肤病学 | 95186篇 |
神经病学 | 302376篇 |
特种医学 | 141790篇 |
外国民族医学 | 506篇 |
外科学 | 551470篇 |
综合类 | 107381篇 |
现状与发展 | 25篇 |
一般理论 | 2301篇 |
预防医学 | 283636篇 |
眼科学 | 81222篇 |
药学 | 247929篇 |
18篇 | |
中国医学 | 10124篇 |
肿瘤学 | 170343篇 |
出版年
2021年 | 50176篇 |
2020年 | 35725篇 |
2019年 | 58785篇 |
2018年 | 72624篇 |
2017年 | 55262篇 |
2016年 | 61373篇 |
2015年 | 74867篇 |
2014年 | 109542篇 |
2013年 | 175941篇 |
2012年 | 96463篇 |
2011年 | 96562篇 |
2010年 | 118220篇 |
2009年 | 122674篇 |
2008年 | 84165篇 |
2007年 | 88278篇 |
2006年 | 98455篇 |
2005年 | 93866篇 |
2004年 | 95706篇 |
2003年 | 87005篇 |
2002年 | 76753篇 |
2001年 | 111542篇 |
2000年 | 104946篇 |
1999年 | 100753篇 |
1998年 | 59853篇 |
1997年 | 57627篇 |
1996年 | 54999篇 |
1995年 | 55797篇 |
1994年 | 50139篇 |
1993年 | 46780篇 |
1992年 | 71569篇 |
1991年 | 68128篇 |
1990年 | 65016篇 |
1989年 | 64307篇 |
1988年 | 60131篇 |
1987年 | 58819篇 |
1986年 | 56277篇 |
1985年 | 56018篇 |
1984年 | 50412篇 |
1983年 | 45536篇 |
1982年 | 42075篇 |
1981年 | 39496篇 |
1980年 | 37332篇 |
1979年 | 42718篇 |
1978年 | 37159篇 |
1977年 | 33961篇 |
1976年 | 30790篇 |
1975年 | 30481篇 |
1974年 | 32300篇 |
1973年 | 30984篇 |
1972年 | 29487篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
51.
兰展仇洪冯磊黄章峰禤义张传东盘丽华 《中国临床神经外科杂志》2022,27(2):107-109
目的 探讨人胶质母细胞瘤(GBM)组织微小核糖核酸-4516(miR-4516)的表达情况及其与病人预后的关系。方法选取 2015年 1月~2019年 5月手术切除的 GBM组织 89例和颅脑损伤内减压术切除的非肿瘤脑组织 35例为对照组,采用 qRT-PCR检测 miR-4516的表达水平,根据 miR-4516表达水平的中位数分为高表达和低表达。GBM病人术后随访 2年,记录生存情况。结果 GBM组织 miR-4516表达水平([ 5.32±1.75)]明显高于对照组([ 1.13±0.45);P<0.01]。术后 2年随访,42例(47.19%)生存,47例 47(52.81%)死亡。多因素 Cox回归分析显示,miR-4516高表达是 GBM生存预后病例的独立危险因素(P<0.05)。生存曲线分析显示 miR-4516高表达组 2年累积生存率(27.45%)明显低于低表达组(73.68%;P<0.001)。结论 GBM组织 miR-4516表达增高,其高表达是病人预后不良的危险因素。 相似文献
52.
Medicine, Health Care and Philosophy - Clinical ethics consultants respond to a multitude of issues, ranging from the cognitive to the emotional. As such, ethics consultants must be prepared to... 相似文献
53.
54.
55.
56.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
57.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献
58.
Ali Soroush Reza Malekzadeh Gholamreza Roshandel Masoud Khoshnia Hossein Poustchi Farin Kamangar Paul Brennan Paolo Boffetta Sanford M. Dawsey Christian C. Abnet Julian A. Abrams Arash Etemadi 《International journal of cancer. Journal international du cancer》2023,152(6):1137-1149
Prior studies have conflicting findings regarding the association between gastroesophageal reflux disease (GERD) and esophageal squamous cell carcinoma (ESCC). We examined this relationship in a prospective cohort in a region of high ESCC incidence. Baseline exposure data were collected from 50 045 individuals using in-person interviews at the time of cohort entry. Participants were followed until they developed cancer, died, or were lost to follow up. Participants with GERD symptoms were categorized into any GERD (heartburn or regurgitation), mixed symptoms, or heartburn alone. Multivariable Cox regression was used to assess the relationship between GERD symptom group and histologically confirmed ESCC. The model was adjusted for known risk factors for GERD and ESCC. 49 559 individuals were included in this study, of which 9005 had GERD symptoms. Over 13.0 years of median follow up, 290 individuals were diagnosed with ESCC. We found no association between any GERD and risk of ESCC (aHR 0.90, 95% CI: 0.66-1.24, P = .54). Similar findings were observed for the GERD symptom subtypes. Significant interactions between any GERD and sex (P = .013) as well as tobacco smoking (P = .028) were observed. In post-hoc analyses, GERD was associated with a decreased risk of ESCC in men (aHR 0.51, 95% CI: 0.27-0.98 P = .04) and in smokers (aHR 0.26, 95% CI: 0.08-0.83 P = .02). While there was little evidence for an overall association between GERD symptoms and ESCC risk, significant interactions with sex and smoking were observed. Men and smokers with GERD symptoms had a lower risk of ESCC development. 相似文献
59.
60.